focus -WSS

focus

author：explore 2025-09-06 06:16:49 - browse：83898

A person picking up medication at a drive through pharmacy window – biotech and pharma coverage from STAT — Adobe

On Tuesday morning, the Department of Health and Human Services unveiled its long-awaited list of the 10 medicines that will be subject to price negotiation in 2026 under the Inflation Reduction Act.

This will mark the first time that Medicare, the government program for paying for health care for older Americans, will have any ability to use its vast size to negotiate for lower prices. It’s not yet clear how big the discounts on these 10 drugs will be, or even if the law will hold up to multiple legal challenges from the pharmaceutical industry. It’s also not clear, as critics from the drug industry have noted, whether any savings to the government will be passed on to consumers.

Still, the naming of 10 medicines is a milestone, and a point to start appraising the impact of the law. The landscape here is complicated. No one really knows how the IRA’s price negotiation process will play out over the short and long term, and many companies who had products named were spared in other ways, with products many industry watchers expected to see on the list absent. Here is STAT’s assessment of who has won and lost.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Drug repurposing or repositioning? The language matters
Next article： Study: Lilly Alzheimer's therapy slowed patients' cognitive decline

focus

explore

WSS

Hawaii wildfires fueled by Hurricane Dora's winds prompt evacuations

Anavex keeps shifting the goalposts in its clinical trials

Ask STAT: What do you want to know about ChatGPT in medicine?

Emergent cuts jobs, executive role in business shake

Study: Lilly Alzheimer's therapy slowed patients' cognitive decline

Do masks work? RCTs can't tell us

hotspot

focus

Wikipedia

Tori Bowie and the unacceptable rates of Black maternal death

NIH trials fail to test meaningful long Covid therapies, experts say

Duchenne breakthrough therapy leaves behind pioneering families

Why drug prescriptions should include diagnoses

Malaria cases in Florida and Texas: Here’s what you need to know

Obesity experts on risks of Wegovy, Ozempic weight loss drugs

Tori Bowie and the unacceptable rates of Black maternal death

Disclosing genetic information: not as worrisome as once feared

In age of alternative facts, a scholarly course on calling out crap

What is the Wagner Group? The 'brutal' Russian military unit in Ukraine

leisure time

Why drug prescriptions should include diagnoses

American woman, child freed after being kidnapped in Haiti last month

Police still searching for prisoner who escaped from NYC hospital

Obesity experts on risks of Wegovy, Ozempic weight loss drugs

Methadone doses haven’t kept up in the age of fentanyl

FDA grants conditional OK to Sarepta’s gene therapy for Duchenne

hotspot

focus

explore

explore